ArticleJournal of orthopaedic surgery and research2025
Serum methylmalonic acid levels predict multisite bone mineral density decline in patients with suspected mitochondrial dysfunction.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study leverages NHANES data to examine the relationship between methylmalonic acid (MMA), a marker of mitochondrial dysfunction, and bone mineral density (BMD). Multivariable linear regression reveals a negative correlation between log10-transformed MMA(Log10 MMA) levels and BMD, along with nonlinear dose-response relationships. Elevated MMA levels are associated with lower BMD, suggesting a negative impact on bone health and highlighting the importance of metabolic regulation in osteoporosis prevention and areas for further research.
methodsUsing NHANES data, multivariable linear regression analyzed the association between log10-transformed MMA levels and BMD, considering covariates like age, race and education. MEC weights were applied to adjust for the complex survey design, and weighted restricted cubic spline (RCS) analyses were used to visualiz the dose - response relationships.
resultsThe study included 19,393 participants. Log10 MMA levels showed negative associations with BMD across skeletal sites (P < 0.0001 in final models), and nonlinear relationships were identified through restricted cubic spline analysis (P < 0.05). Stratified analyses confirmed consistent associations without significant interactions.
conclusionElevated MMA levels, indicative of mitochondrial dysfunction, are significantly associated with lower BMD at multiple skeletal sites. This suggests that mitochondrial metabolic disturbances may compromise bone health, highlighting the importance of metabolic regulation in osteoporosis prevention and management, and emphasizing the need for further research into the mechanisms and treatments.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.